We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

IPK and Euroscreen Form Alliance for GPCR Drug Discovery

IPK and Euroscreen Form Alliance for GPCR Drug Discovery

IPK and Euroscreen Form Alliance for GPCR Drug Discovery

IPK and Euroscreen Form Alliance for GPCR Drug Discovery

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IPK and Euroscreen Form Alliance for GPCR Drug Discovery"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Institute Pasteur Korea (IPK) and Euroscreen s.a. have announced a partnership to perform screening of G protein coupled receptors using internalization assays.

The development at the Institute Pasteur Korea of a visual-based High Throughput Screening platform is designed to offer opportunities for the identification of drug candidates activating receptor internalization while Euroscreen’s receptor cell lines and GPCR library compounds will provide the initial direction and components for this drug discovery collaboration.

This partnership takes thus advantage of both IPK expertise in the image analysis and HCS fields and Euroscreen competence in GPCR biology and Chemistry tools.

"We are delighted to be working with Euroscreen s.a. on this GPCR Drug Discovery project," commented Dr. Thierry Christophe, Head of Screening Technologies and Pharmacology at Institute Pasteur Korea.

"This partnership highlights the increasing interest in visual-based screening technologies to identify more selective drug candidates. It validates the screening approach we develop at IPK."

"Collaborating with one of the World’s leaders in the GPCR science sector signifies an important step in materialising IPK’s innovative approach. We are enthusiastic to have found a highly competent partner in Euroscreen, to take HCS screening to the next level," added Dr. Ulf Nehrbass, Director and CEO of IPK.

"This should provide our companies with a rapid, joint opportunity to develop drug candidates which selectively cause the internalization of GPCRs for their therapeutic action in vivo," said Dr. François Roman, the Head of Drug Development R&D at Euroscreen.